As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of OS Therapies Inc. The largest reported stake is Thomas A. Satterfield, Jr.'s, at 9.4%. 2 filings are on record since August 13, 2025 (Schedule 13G/A, August 13, 2025).
Sell to companies like OS Therapies Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
OS Therapies Inc has 2 Schedule 13D or 13G filings on record since 2025-08-13. 2 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Thomas A. Satterfield, Jr. | 9.4% | 3,115,681 | SCHEDULE 13G/A, 2025-08-13 | 2025-06-30 |
| 8.5% | 2,677,570 | SCHEDULE 13D/A, 2025-08-18 | 2025-07-29 |
Holding shares or following this stake? See who's behind OS Therapies Inc and the warning signs.
Free to see. No signup.
Keep reading
More on OS Therapies Inc and the records around it.
OS Therapies Inc elsewhere on the record
- Company profile and every filing Oct 2026
- Form D filing Oct 2026
- Leadership changes Sep 2026
- Form D filing Aug 2026
- Who owns it
Companies that share a holder
- Thomas A. Satterfield, Jr. also filed stake reports on 8 other companies: Lantern Pharma Inc. (Jul 2026), Curis, Inc. (May 2026), enVVeno Medical Corporation (Nov 2025)
Watch OS Therapies Inc
Get an email when OS Therapies Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on OS Therapies Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on OS Therapies Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on OS Therapies Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
12 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Thomas A. Satterfield, Jr. | 296,930 | 2,818,751 | 296,930 | 2,818,751 | SCHEDULE 13G/A, 2025-08-13 |
| Shalom Auerbach | 2,677,570 | 0 | 2,677,570 | 0 | SCHEDULE 13D/A, 2025-08-18 |
| Einodmil LLC | 2,654,199 | 0 | 2,654,199 | 0 | SCHEDULE 13D/A, 2025-08-18 |
The latest filing identifies OS Therapies Inc by CUSIP 68764Y207 and gives its principal executive office as 115 Pullman Crossing Road, Suite #103, Grasonville, MD 21638 (SCHEDULE 13D/A, 2025-08-18).
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby supplemented as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Amendment and the information set forth in or incorporated by reference in Item 5 of this Amendment is hereby incorporated by reference in its entirety into this Item 3. On July 3, 2025, Einodmil sold 10,000 shares of Common Stock, which were effected on the open market at a price per share of approximately $2.10 for proceeds of approximately $20,695 (the "July 3, 2025 Sales").Shalom Auerbach, SCHEDULE 13D/A, 2025-08-18
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-13 | Thomas A. Satterfield, Jr. | 9.4% | SCHEDULE 13G/A |
| 2025-08-18 | Shalom Auerbach | 8.5% | SCHEDULE 13D/A |
Questions about who owns OS Therapies Inc
Who owns OS Therapies Inc?
On this page, 2 holders' latest ownership filings report 5% or more of OS Therapies Inc: Thomas A. Satterfield, Jr. (9.4%, Schedule 13G/A, filed 2025-08-13) and Shalom Auerbach (8.5%, Schedule 13D/A, filed 2025-08-18).
Who are the largest shareholders of OS Therapies Inc?
By the share each holder's latest filing reports, the largest holders of OS Therapies Inc on this page are Thomas A. Satterfield, Jr. (9.4%) and Shalom Auerbach (8.5%).
When did Thomas A. Satterfield, Jr. buy into OS Therapies Inc?
The filings give report dates, not purchase dates. The earliest filing from Thomas A. Satterfield, Jr. on this page is the Schedule 13G/A, filed 2025-08-13, reporting 9.4%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for OS Therapies Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 23, 2026 | Form D, private offering | $7.17M sold | Form D page | Source |
| October 5, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| August 25, 2026 | Form D, private offering | $5M sold | Form D page | Source |
| July 16, 2026 | Form D, private offering | $1.60M sold | Form D page | Source |
| July 2, 2026 | Leadership change: Karim Galzahr departs, Director, and 1 more | — | Leadership changes | Source |
| March 6, 2026 | Form D, private offering | $2M sold | Form D page | Source |
| January 20, 2026 | Form D, private offering | $3.50M sold | Form D page | Source |
| September 10, 2025 | Form D, private offering | $3.78M sold | Form D page | Source |
| July 16, 2025 | Form D, private offering | $4.22M sold | Form D page | Source |
| January 22, 2025 | Form D, private offering | $7.10M sold | Form D page | Source |
OS Therapies Inc: every filing and event
Tools for this story
Each opens in a new tab, filled in for OS Therapies Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.